Genflow Strengthens IP Portfolio
Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has filed for patent examination in China for its SIRT6 Variants targeting Non-Alcoholic Steatohepatitis (NASH). The patent application covers proprietary variants of the SIRT6 gene designed to address NASH, a severe progressive liver disease with limited treatment options.
This strategic move strengthens Genflow's global intellectual property portfolio and demonstrates its commitment to expanding its presence in one of the world's largest healthcare markets. The company aims to develop innovative SIRT6-based therapies to transform NASH treatment.
Genflow Biosciences (OTCQB:GENFF), l'unica azienda europea quotata pubblicamente nel settore della longevità, ha presentato una domanda di esame di brevetto in Cina per le sue Varianti SIRT6 mirate alla Non-Alcoholic Steatohepatitis (NASH). La domanda di brevetto riguarda varianti proprietarie del gene SIRT6 progettate per affrontare la NASH, una grave malattia epatica progressiva con opzioni di trattamento limitate.
Questo movimento strategico rafforza il portafoglio globale di proprietà intellettuale di Genflow e dimostra l'impegno dell'azienda ad espandere la propria presenza in uno dei mercati sanitari più grandi al mondo. L'azienda punta a sviluppare terapie innovative basate su SIRT6 per trasformare il trattamento della NASH.
Genflow Biosciences (OTCQB:GENFF), la única empresa europea cotizada públicamente en longevidad, ha presentado una solicitud de examen de patente en China para sus variantes de SIRT6 dirigidas a la Esteatohepatitis No Alcohólica (NASH). La solicitud de patente abarca variantes propietarias del gen SIRT6 diseñadas para abordar la NASH, una enfermedad hepática progresiva grave con opciones de tratamiento limitadas.
Este movimiento estratégico fortalece la cartera global de propiedad intelectual de Genflow y demuestra su compromiso de expandir su presencia en uno de los mercados de salud más grandes del mundo. La empresa tiene como objetivo desarrollar terapias innovadoras basadas en SIRT6 para transformar el tratamiento de la NASH.
Genflow Biosciences(OTCQB:GENFF), 유럽에서 유일하게 상장된 장수 기업으로, SIRT6 변이체를 비알코올성 지방간염(NASH)을 겨냥한 중국 특허 심사에 접수했다. 특허 출원은 NASH를 다루도록 설계된 SIRT6 유전자의 독점 변이체를 포함하며, 치료 옵션이 제한된 심각한 진행성 간 질환이다.
이 전략적 움직임은 Genflow의 글로벌 지식 재산 포트폴리오를 강화하고 세계 최대 보건 시장 중 하나에서 입지를 확대하려는 의지를 보여준다. 회사는 NASH 치료를 혁신적으로 바꿀 SIRT6 기반 치료제를 개발하는 것을 목표로 한다.
Genflow Biosciences (OTCQB:GENFF), la seule entreprise européenne cotée publiquement dans le domaine de la longévité, a déposé une demande d'examen de brevet en Chine pour ses variantes de SIRT6 ciblant la stéatohépatite non alcoolique (NASH). La demande de brevet couvre des variantes propriétaires du gène SIRT6 conçues pour traiter la NASH, une maladie hépatique grave et progressive avec des options de traitement limitées.
Cette démarche stratégique renforce le portefeuille de propriété intellectuelle mondial de Genflow et démontre son engagement à étendre sa présence sur l’un des plus grands marchés de soins de santé au monde. L'entreprise vise à développer des thérapies innovantes basées sur SIRT6 pour transformer le traitement de la NASH.
Genflow Biosciences (OTCQB:GENFF), Europas einziges börsennotiertes Unternehmen im Bereich Langlebigkeit, hat in China eine Patentanmeldung für seine SIRT6-Varianten eingereicht, die auf die Nicht-alkoholische Fettlebererkrankung (NASH) abzielen. Der Patentantrag deckt eigentümliche Varianten des SIRT6-Gens ab, die darauf ausgelegt sind, NASH zu behandeln, eine schwere fortschreitende Leberkrankheit mit begrenzten Behandlungsmöglichkeiten.
Dieser strategische Schritt stärkt Genflows globales Portfolio an geistigem Eigentum und demonstriert sein Engagement, seine Präsenz in einem der weltweit größten Gesundheitsmärkte auszubauen. Das Unternehmen will innovative auf SIRT6 basierende Therapien entwickeln, um die Behandlung von NASH zu transformieren.
Genflow Biosciences (OTCQB:GENFF)، الشركة الأوروبية الوحيدة المدرجة علناً في مجال الشيخوخة، قدمت طلب فحص براءة اختراع في الصين لنسخ SIRT6 التي تستهدف التهاب الكبد الدهني غير الكحولي (NASH). يغطي طلب البراءة نسخاً مملوكة من جين SIRT6 مصممة لمعالجة NASH، وهو مرض كبدي تقدمي خطير مع خيارات علاج محدودة.
هذه الخطوة الاستراتيجية تقوي محفظة الملكية الفكرية العالمية لشركة Genflow وتُظهر التزامها بتوسيع حضورها في أحد أكبر أسواق الرعاية الصحية في العالم. وتهدف الشركة إلى تطوير علاجات جديدة قائمة على SIRT6 لتغيير علاج NASH.
Genflow Biosciences (OTCQB:GENFF)，欧洲唯一公开上市的长寿领域公司，已就其针对非酒精性脂肪性肝炎（NASH）的 SIRT6 变体向中国提交专利审查申请。该专利申请涵盖为治疗 NASH 而设计的 SIRT6 基因的专有变体，NASH 是一种严重的进行性肝病，治疗选择有限。
这一战略举措增强了 Genflow 在全球的知识产权组合，体现了其在全球最大的医疗保健市场之一扩张业务的承诺。公司目标是开发基于 SIRT6 的创新治疗方法，以改变 NASH 的治疗现状。
- Patent application strengthens IP protection in China's large healthcare market
- Expansion of global intellectual property portfolio for NASH treatment
- Strategic positioning in market with limited treatment options
- None.
Genflow Strengthens Global IP Portfolio with China Patent Examination Filing for SIRT6 Variants in NASH
LONDON, UK / ACCESS Newswire / September 19, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, today announces that it has filed a formal request for the examination of its patent application entitled SIRT6 Variants for NASH in China.
The application covers proprietary variants of the SIRT6 gene designed to address Non-Alcoholic Steatohepatitis (NASH), a severe progressive liver disease with limited treatment options. By pursuing examination in China, Genflow is reinforcing its global intellectual property portfolio and furthering its commitment to developing innovative therapies for patients worldwide.
Dr. Eric Leire, CEO of Genflow, commented: "The filing of this examination request in China represents another significant step in protecting our technology in one of the world's largest healthcare markets. We are committed to advancing our research into SIRT6-based therapies and believe that our approach holds strong potential to transform the treatment landscape for NASH."
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
Corporate Brokers | |
Capital Plus Partners Ltd | |
Jon Critchley, |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What patent did Genflow (GENFF) file for examination in China?
Why is Genflow's NASH patent application in China significant?
What is Genflow (GENFF) developing for NASH treatment?
Is Genflow Biosciences the only listed longevity company in Europe?
